Business Wire

Valbiotis Consolidates Its Development of Innovative Natural Health Solutions by Integrating the Exploration of Microalgae Produced in New Caledonia, Through an Exclusive Agreement With ADECAL-Technopole and IFREMER

Share

Regulatory News:

Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a French research and development company committed to scientific innovation for preventing and combating of metabolic diseases, announces the consolidation of its development of innovative natural health solutions, by integrating the exploration of microalgae produced in New Caledonia, through an exclusive agreement with ADECAL-Technopole and IFREMER. This program should allow to develop a bank of high-potential strains selected by ADECAL-Technopole and IFREMER since 2013 in New Caledonia as part of the "AMICAL" joint research project.

Valbiotis will carry out the work necessary to demonstrate the health benefits of these microalgae strains at its preclinical platform in Riom, with a view to filing new patents. Once this scientific validation has been achieved, production will be ensured in New Caledonia for the industrial scale-up, thanks to existing and operational pilot infrastructure for which the technology and know-how will be transferred to private operators. For their marketing, these new health solutions will need to obtain "GRAS" regulatory status in the United States and "Novel Food" status in Europe. They may be incorporated into foodstuffs, presented in the form of food supplements or formulated as medical nutrition.

The tripartite agreement with ADECAL-Technopole and IFREMER provides for exclusive commercial exploitation rights of these microalgae for Valbiotis1. The microalgae market will grow at an annual rate of 3.5% to reach $3.8 billion by 20242.

Sébastien PELTIER, CEO, Chairman of the Board of Directors of Valbiotis, comments: "This is a Research & Development program that has been close to my heart for many years and that I am delighted to be able to implement today with ADECAL-Technopole and IFREMER. The use of plant resources, both terrestrial and marine, can provide a solution to tomorrow's health needs. This growing market benefits from the strong worldwide demand for innovative, natural and effective molecules for health. Since the identification and combination of active plant substances is central to our expertise, it makes perfect sense to extend our know-how to marine biotechnologies and microalgae, the beneficial properties of which should lead to the filing of new patents. In addition, contributing to the development of an innovative microalgae production sector in New Caledonia, participating in local economic growth and enhancing the biodiversity of the lagoon in the long term are important sustainable development objectives for Valbiotis."

Adrien RIVATON, Managing Director of ADECAL-Technopole, explains:"We have developed a marine cluster in order to contribute to the development of the blue economy and more specifically to promote the development of the aquaculture and marine biotechnology sectors, based on the richness of local marine ecosystems, whose potential for valorization is still largely under-exploited. The research collaboration with Valbiotis opens up new opportunities for experimentation on microalgae and promising prospects for our territory."

Romain CHARRAUDEAU, Director of Partnership and Innovation Transfer at IFREMER adds: "IFREMER is a place where knowledge and skills in research, technology and innovation concerning the marine environment are brought together. It plays an inspiring and galvanizing role, ensuring the engagement of scientific communities through partnership approaches that involve public & private actors in the development and implementation of research programs. The research collaboration with Valbiotis has been concluded within the framework of this strategy."

Valbiotis, ADECAL-Technopole and IFREMER are committed to respecting the three pillars of the Nagoya Protocol which came into force on October 12, 2014 and stems from the Convention on Biological Diversity. As such, they are committed to carrying out their research and development activities in accordance with the applicable ABS3 regulations and to ensuring traceability with the competent authorities before the implementation of any research program requiring the use of biological material.

Microalgae: a resource of the future for human food and health

These marine plant organisms, more commonly known as "phytoplankton", are about a micrometer in size and constitute a remarkable source of biodiversity, still largely unexplored, and an abundant resource that can be exploited by marine biotechnologies.

These fast-growing microorganisms use light to generate a biomass rich in proteins, lipids and sugars, bioactive compounds (polyphenols, tocopherols, ascorbic acid) and pigments (chlorophyll, carotenoids, phycobilins)4,5. The diversity of these molecules of interest and their ease of production offer tremendous potential for innovation in the nutrition and health sectors, but also in energy, chemistry and cosmetics, with industrial applications already available4,5. In the health field, microalgae have, for example, antibacterial, antifungal, anti-free radical, anti-inflammatory and anti-tumor properties5.

The microalgae market will grow at an annual rate of 3.5% to reach $3.8 billion by 20242.

AMICAL: a microalgae development program, launched in 2013 by Adecal-Technopole and IFREMER in New Caledonia

Resulting from a collaboration and co-ownership agreement between the LEAD unit of IFREMER (Lagoons, Ecosystems and Sustainable Aquaculture in New Caledonia) and ADECAL-Technopole, the joint research program "AMICAL" aims to develop an innovative microalgae production chain in New Caledonia and to valorize the results of research in this field. It has received funding from New Caledonia, the three Provinces and the French State.

Since 2013, the Laboratoire d'Étude des Micro-Algues (LEMA) and the Laboratoire Technologique des Micro-Algues (LTMA) have conducted their bioprospecting operations in New Caledonian coastal waters to select species with high growth potential and build a strain library of New Caledonian microalgae of interest.

The research has mainly focused on the biochemical characterization of the selected microalgae: energy content, proteins and amino acids, lipids and fatty acids, sugars and natural bioactive substances with high added value for applications in nutrition and health. This strain selection work paves the way for preclinical experiments which Valbiotis will be responsible for under the tripartite agreement.

About IFREMER
IFREMER is a public body of an industrial and commercial nature. It contributes to the French research and innovation system, as well as to the European research area, through the production of fundamental knowledge via a systemic approach enabling a better understanding of the processes that govern ecosystems and the changes that affect them. IFREMER is also involved in economic development through numerous partnerships with industry and the economy, and the promotion of the Institute's innovations.

About ADECAL
ADECAL Technopole is an association under the French law of 1901, mainly financed by the French State, New Caledonia and its three provinces. It works to promote the competitiveness and attractiveness of New Caledonia through experimentation, transfer and innovation, and comprises four clusters (marine, land, agri-food and innovation) as well as technology centers. ADECAL Technopole contributes to the development of natural marine and terrestrial resources as well as to the emergence of innovative projects and sectors, in favor of sustainable development in order to diversify the New Caledonian economy.

About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based terrestrial and marine resources.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France - Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada) .
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com

Name: Valbiotis
ISIN code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document approved by the French Financial Markets Regulator (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company’s website (www.valbiotis.com).
This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.


1The field of operation is defined as follows: "Nutraceuticals, drugs and medical devices in human and animal health in the strict context of the prevention and treatment of the following metabolic diseases: diabetes, dyslipidemia, hypertension, overweight, obesity, NAFLD (Non-alcoholic fatty liver disease)."
2Global Microalgae Market Growth 2019-2024, Fior Markets, 2019; https://www.fiormarkets.com/report/global-microalgae-market-growth-2019-2024-372987.html
3The regulation of access and benefit sharing from the use of genetic resources and associated traditional knowledge (ABS).
4Microalgae: behind the scenes of a revolution, Le Journal du CNRS, April 2019; https://lejournal.cnrs.fr/diaporamas/microalgues-les-coulisses-dune-revolution
5Microalgae Aquaculture in New Caledonia (AMICAL), IFREMER, June 2016; https://nouvelle-caledonie.ifremer.fr/Biodiversite-et-ressources/Aquaculture-de-micro-algues

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Corporate communication / Valbiotis
Carole ROCHER / Marc DELAUNAY
+33 5 46 28 62 58
media@valbiotis.com

Financial communication / Actifin
Stéphane RUIZ
+33 1 56 88 11 14
sruiz@actifin.fr

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NTT: CEOs Say People and the Planet Are Becoming More Important in Business18.10.2021 08:15:00 CEST | Press release

WSJ Intelligence undertook a new international CEO survey for global technology and business solution provider NTT. The survey focuses on the role of business in contributing to societal goals. WSJ Intelligence conducted a survey of 351 CEOs of large corporations representing ten key industries in 15 countries to understand their views on their organization’s role in society, social impact strategies, the stakeholders involved, and how the Covid-19 pandemic has driven these strategies. The research confirms that post-pandemic people and the planet rather than solely profit are becoming increasingly important for organizations of all sizes. While this trend was evident before March 2020, the pandemic brought it to the forefront. The latest research considers, too, how organizations better support employee wellbeing and change management. It uncovers the most valuable tools and tips for social purpose implementation while also analyzing the most significant challenges. Key Findings: 94%

"THE GUNPLA SHOWROOM DUBAI"18.10.2021 08:00:00 CEST | Press release

BANDAI SPIRITS Co., LTD. (President and Chief Executive Officer: Nao Udagawa, Head Office: Minato-ku, Tokyo) will be operating "THE GUNPLA SHOWROOM DUBAI" from late October, 2021 to March 31, 2022, at the Dubai Mall, a shopping mall in Dubai in the city of Dubai in the United Arab Emirates, concurrently with Expo 2020 Dubai that will begin on October 1, 2021. Given the appointment of Gundam as the "PR Ambassador of the Japan Pavilion, Expo 2020 Dubai", we will be promoting Japanese culture and the joy of monodukuri (creating and crafting) to people around the world through Gunpla (Gundam-series plastic models). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211017005004/en/ Display of 1/10 scale standing Gundam statue (Photo: Business Wire) Description of "THE GUNPLA SHOWROOM DUBAI" Exhibit of 1/10 Scale Standing Gundam Statue 1/10 scale standing statue of RX-78-2 (total height: approximately 1,800 mm) will be on exhibit. Lo

Antin Infrastructure Partners to Become Majority Shareholder in Origis Energy, a Leading U.S. Renewable Energy Platform18.10.2021 07:30:00 CEST | Press release

Regulatory News: Antin Infrastructure Partners (Ticker: ANTIN – ISIN: FR0014005AL0), one of the world’s leading infrastructure investment firms, announced today that funds managed by Antin have entered into a definitive agreement to acquire a majority stake in Origis Energy, a major vertically integrated renewable energy platform in the United States, from its CEO & President Guy Vanderhaegen and Global Atlantic Financial Group. The company focuses on developing, building, and operating utility-scale solar and storage assets, as well as distributed generation. Guy Vanderhaegen will continue to lead and to hold a significant stake in the company. Founded in 2008, Origis Energy has a track record of development success across 130 solar and storage projects. Antin will support Origis Energy with additional capital and resources as it builds out its contracted pipeline, which is one of the largest in the U.S. and provides clear visibility into its growth plan over the next several years. T

Nexign Completed Campaign Management Solution for Middle East Telecom Operator Zain Kuwait18.10.2021 07:00:00 CEST | Press release

Nexign (part of ICS Holding), an international provider of business support systems (BSS), has announced that the company completed the Marketing Campaign Management system implementation for Zain Kuwait, one of the leading telecom service providers in the Middle East, in cooperation with the Turkcell Technology, a subsidiary of Turkcell, a converged telecommunication and technology services provider, founded and headquartered in Turkey. The implemented system enables Zain Kuwait to provide targeted offerings to a wide range of its subscribers and boost customer loyalty and retention. Marketing Campaign Management System is a BI-integrated solution for diversified campaigns management during the customer lifecycle. It provides selection rules management to define target segments and communication channels to schedule, execute and track the performance of marketing campaigns. The system enables the company to increase response rates and make sales and marketing initiatives more effectiv

Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL318.10.2021 07:00:00 CEST | Press release

Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accent’s pre-clinical stage METTL3 program. Acute myeloid leukemia (AML) is a difficult to treat cancer of the blood and bone marrow, accounting for a third of all new cases of leukemia in the US each year.1 Globally, the incidence of AML has been increasing year on year across the last 20 years.2 RNA modifying proteins (RMPs) are an emerging target class that control multiple aspects of RNA biology and represent a new approach for the potential treatment of various cancers. METTL3 is an RMP that has been validated pre-clinically as a novel therapeutic target for AML.1,3 This collaboration combines Accent’s expertise in RMP-targeting therapeutics with Ipsen’s capabilities and proven track record in Oncology medicine devel

First-ever Winners of Prince William’s Earthshot Prize announced at star-studded London Awards Ceremony17.10.2021 22:00:00 CEST | Press release

The Earthshot Prize has tonight revealed the first-ever five Winners at a glittering ceremony held in London. Each Winner will receive £1million prize money and a global network of support to scale their cutting-edge environmental solutions to repair our planet. The five Winners, which span the globe from Costa Rica to India, include transformative technologists, innovators, an entire country, and a pioneering city and were chosen for their ground-breaking solutions to the greatest environmental challenges facing our planet. Earthshot Prize Founder and Prize Council Member Prince William said: “Our five inspirational Winners show that everyone has a role to play in the global effort to repair our planet. We need businesses, leaders, innovators, and communities to take action. And, ultimately, we need all of us to demand that the solutions get the support they need. Because the success of our Winners is our collective, global Earthshot.” Earthshot Prize Council Member Sir David Attenbor

Janssen Receives Positive CHMP Opinion for RYBREVANT ® (amivantamab) for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy15.10.2021 18:30:00 CEST | Press release

FOR EU TRADE AND MEDICAL MEDIA ONLY. NOT TO BE DISTRIBUTED TO UK AND BENELUX BASED MEDIA The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product amivantamab, intended for the treatment of adult patients with advanced NSCLC with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations, after failure of platinum-based therapy.3 If approved, amivantamab will be the first treatment in the European Union specifically targeting EGFR exon 20 insertion mutations for advanced NSCLC.1 “This group of patients often face a poor prognosis as there are currently no targeted therapy options for this specific mutation nor does it typically respond to existing therapies used to treat more common EGFR mutations,” 1,4,5 commented Catherine Taylor, M.D., Vice President, Medical Affairs